NasdaqCM:CLDXBiotechs
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress
Earlier this week, Celldex Therapeutics reported its second quarter 2026 results, showing revenue of just US$22,000 and a net loss of US$73.5 million, alongside a wider first-half loss of US$152.19 million.
At the same time, the company updated investors on its clinical pipeline, highlighting positive Phase 1 data for bispecific antibody CDX-622 and continued progress of barzolvolimab into late-stage studies despite discontinuing a prurigo nodularis program.
Next, we’ll examine how the...